Montreal's EMcision launches catheters for pancreatic cancer

EMcision's RF Duo 13 has gone to market in Europe and China.--Courtesy of EMcision

Canadian devicemaker EMcision International has sold the first units of its pancreatic tumor ablation catheter, the Habib RF Duo 13, in Europe and China, notching a foothold to gain further insight into the device's efficacy.

Named after the Montreal company's founder, surgeon and inventor Nagy Habib, the CE-marked RF Duo 13 is designed to cauterize and coagulate tissue deep in the pancreas using radiofrequency to destroy malignant tumor cells, according to EMcision. The shipment of over 40 units in Europe and China will give the company the necessary clinical data to boost sales of the device in the future.

"The RF Duo 13 is groundbreaking and has real potential to improve the lives of those suffering from pancreatic cancer," EMcision CEO Cherif Habib said in a statement. "We are honored that top international surgeons have decided to begin a trial period with our minimally invasive product."

EMcision began developing its line of radiofrequency devices more than a decade ago; its Habib 4X catheter for liver cancer is one of the top hepatic resection devices in the U.S., according to the company.

- here's the release

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.